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CD94/NKG2A is an inhibitory receptor expressed by NK cells and cytotoxic lymphocytes
and, upon activation by HLA-E, downregulates the cytolytic activities of these cells thus
representing a tumour immune escape mechanism.
This study was aimed at assessing whether cytotoxic lymphocytes (CD8+) and NK cells
from malignant pleural effusions have a deregulated expression of CD94/NKG2A.
The expression of membrane CD94/NKG2A and perforin was evaluated by flow-cytometry
in CD8+ and NK cells from pleural effusions and autologous peripheral blood of cancer
(n = 19) andcongestiveheart failure (CHF) (n = 11) patients. IntracellularCD94/NKG2Aexpres-
sion was evaluated by flow-cytometry in pleural effusion CD8+ and NK cells from cancer
patients (n = 10). Cytotoxic activity against cancer cells exerted by pleural and autologous
peripheral blood T lymphocytes from cancer patientswas assessed by flow-cytometry assay.
Pleural CD8+ from cancer patients showed a reduced expression of membrane CD94/
NKG2A and perforin when compared to autologous peripheral blood and CHF pleural effu-
sions. Reduced numbers of NK cells were present in pleural effusions from both cancer
and CHF patients. Pleural NK from cancer patients showed a reduced expression of mem-
brane CD94/NKG2A and perforin when compared to autologous peripheral blood. Pleural T
lymphocytes from cancer patients exhibited a reduced cytotoxic activity against cancer cells
when compared to autologous peripheral blood T lymphocytes. The intracellular expression
of CD94/NKG2A in CD8+ and NK cells from cancer patients was higher than membrane
expression.
In conclusion, this study provides compelling evidences of new mechanisms underlying
the reduced host defence against cancer within the pleural space.
 2010 Elsevier Ltd. All rights reserved.1. Introduction malignancies and account for up to 50% of the exudates in
1Malignant pleural effusions are mostly due to metastatic
involvement of the pleural compartment by heterogeneous
primaries and recur in 15% of patients who die wither Ltd. All rights reserved
Biomedicina e Immuno
680 9148; fax: +39 091 6
.many clinical series. Exudative malignant pleural effusions
are characterised by the accumulation of fluid enriched in
proteins and by the recruitment of elevated numbers of
mononuclear cells into the pleural space.2 Host defence.
logia Molecolare, Consiglio Nazionale delle Ricerche, Via Ugo La
80 9122.
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activity of CD8+ cytotoxic T lymphocytes (CTL) and natural
killer (NK) cells.3 CD8+ CTL exert their cytotoxic activity on tu-
mour cells by releasing toxic mediators, such as perforin and
granulysin4 or by inducing cell apoptosis via FAS/FAS ligand
pathway.5 Like CD8+ CTL, NK cells kill tumour target cells
without prior sensitisation, relying on directed exocytosis of
secretory lysosomes and on activation of FAS/FAS ligand-in-
duced cell death. The magnitude and diversity of CD8 positive
CTL- and NK-mediated responses against tumour cells reflect
the outcome of a balance between signals of activation and
inhibition. An accurate and precise control of this balance is
essential for mounting protective anti-tumour responses
and for concurrently limiting potential immunopathologic
complications.6 The CD94/NKG2Aheterodimer is an inhibitory
receptor expressed by CD8+ CTL and NK cells that, upon
activation by HLA-E, downregulates their cytolytic activity
against tumourcells.7Although, somestudieshaveshownthat
pleural effusion mononuclear cells exhibit several functional
defects,8 limited information is available regarding the expres-
sion and the activity of the CD94/NKG2A complex in CD8+ CTL
and NK cells isolated frommalignant pleural effusions.
The aims of the present study were to determine whether
CD8+ CTL and NK cells frommalignant pleural effusions have
a deregulated expression/activation of CD94/NKG2A and
whether this phenomenon may contribute to a reduced cyto-
toxic activity against cancer cells in the pleural compartment.
2. Materials and methods
2.1. Pleural fluid collection
Peripheral blood (PB) and pleural fluid (PF) were obtained from
patients with congestive heart failure (CHF) (n = 11; age range
50–80 years) and cancer (n = 19, age range 45–78 years). Pleural
fluids were collected by thoracentesis, before the initiation of
chemotherapy. All subjects gave informed written consent
and the study was approved by the institutional review board
for human studies and was consistent with Helsinki Declara-
tion. Patients were recruited at the Dipartimento di Medicina
Interna e Specialistica – Universita` di Palermo, in Palermo and
the Dipartimento di Scienze Cliniche, Sezione di Malattie
Respiratorie, Universita` di Parma, in Parma, Italy.
The effusions were first classified as transudates or exu-
dates by meeting at least one of the criteria described by
Light.9 Standard clinical, laboratory, and radiological investi-
gations were used to establish the diagnosis for each patient
as previously described.10 No patients were undergoing anti-
inflammatory or steroid therapies. The fluids were drawn into
polypropylene bags containing heparin (10–20 IU/ml) and
were subsequently centrifuged at 400g for 10 min.
2.2. Mononuclear cells
PB and PF mononuclear cells were isolated by Ficoll-Hypaque
(Pharmacia) gradient centrifugation and, after two washes,
the cells were suspended in RPMI 1640 tissue culture medium
(Invitrogen Life Technologies) supplemented with 10% heat-
inactivated foetal calf serum (FCS) (Invitrogen Life Technolo-
gies), 2 mM L-glutamine, 20 mM HEPES, 100 U/ml penicillin,100 lg/ml streptomycin, 5 · 10–5 M 2-ME and 85 lg/ml genta-
micin. Purity and viability were tested using trypan blue
exclusion.
2.3. Expression of surface markers
PB and PF mononuclear cells were washed twice in PBS (con-
taining 1% FCS and 0.02% Na azide) and thereafter stained
and subjected to flow cytometric analysis. Suspended cells
were stained with FITC-, phycoerythrin-(PE) or phycoery-
thrin-Cy5 (PE-cy5)-conjugated antibodies against CD3, CD4,
CD8, CD19, CD56, CD16 and CD94 [all monoclonal antibodies
(MoAb) were from BD PharMingen]. To identify NK cells, PF
mononuclear cells were depleted from CD3+ cells using CD3
microbeads (Miltenyi Biotec, ergish Gladbach, Germany) using
the MACS cell separation columns, following the manufac-
turer’s instructions. The CD3 depleted cells were then stained
using phycoerythrin (PE)-anti CD16 monoclonal antibody and
PE-cy5 anti-CD56 (Becton-Dickinson, United States). The
CD56+/16+ cells were gated from the total cell population
for assessing CD94/NKG2A or perforin expression using FITC
conjugated antibodies. To assess CD94/NKG2A expression, a
monoclonal antibody (HP-3D9) recognising the dimer Kp43,
formed by the association of CD94 with NKG2A (Mingari
MC, International Immunology 1887), was used. Cells (105)
from each sample were analysed using a FACScalibur sup-
ported with CellQuest acquisition and data analysis software
(Becton Dickinson). The lymphocytes were gated by forward
and side scatter.
2.4. Intracellular staining
For detection of intracellular perforin or intracellular CD94/
NKG2A, freshly isolated PF and PB cells were surface stained
with CD3, CD8 and CD56, in incubation buffer (PBS containing
1% FCS and 0.1% Na azide) for 30 min at 4 C. Cells were then
washed twice in PBSwith1%FCSandfixedwithPBScontaining
4% paraformaldehyde overnight at 4 C. Fixation was followed
by twowashes in permeabilisation buffer with PBS containing
1% FCS, 0.3% saponin and 0.1% Na azide for 15 min at 4 C and
fixed permeabilised cells were stained with antiperforin anti-
body (BD PharMingen Reagent set). After two more washes in
PBS containing 1%FCS, the cellswere analysed by FACSCalibur.
Lymphocyteswere gated by forward and side scatter and anal-
ysis was done on 100,000 acquired events for each sample.
2.5. Cytotoxicity assay
In a flow cytometric test effector CD8+ CTL and NK cells from
PB and PF from cancer patients (n = 8) and from PF from CHF
patients (n = 8) were mixed with H292 target cells labelled
with DiO (3,3 0-dioctadecyloxacarbocyanine perchlorate) at
effector/target cell ratio of 5:1. Dead cells were stained with
propidium iodide and results were expressed as percentage
of cytotoxic activity versus baseline.
2.5.1. Effector cells
Mononuclear cells were separated from PB and PF from can-
cer patients and from PF from CHF patients (n = 5) by Ficoll-
Hypaque density gradient centrifugation and adherent cells
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for 60 min at 37 C. Non-adherent cells were resuspended in
RPMI 1640 medium with 10% FCS and adjusted to
1 · 109 cells/l.
2.5.2. Target cells
NCI-H292 (mucoepidermoid carcinoma), a Non Small Cell
Lung Carcinoma cell line, was maintained in culture in RPMI
1640 medium with 10% FCS at 37 C in a humidified 5% CO2
chamber. H292 cells were labelled with the stain 3,3 0-diocta-
decyloxacarbocyanine perchlorate (DiO, Invitrogen, Molecular
Probes) for 20 min of incubation at 37 C and 5% CO2.
2.5.3. Cell activity assay
CTL and NK activity against H292 target cells was assessed
by a flow-cytometry assay using the DiO membrane dye to
stain live H292 cells and propidium iodide (Sigma–Aldrich,
St. Louis, MO) nuclear dye to stain dead cells. Unstained
effector cells and stained target cells were added to each
of six Falcon polystyrene 12 · 75 (Becton Dickinson, Moun-
tain View, CA) assay tubes at effector/target ratio of 5:1. Con-
trol tubes contained effector and target cells separately.
Propidium iodide was added (13 mg/tube) and the tubes were
incubated in a 5% CO2 atmosphere at 37 C for 2 h. The use
of flow-cytometry (FACScalibur D275) in combination with
propidium iodide permitted the differentiation of four cell
populations: live target cells (upper left), dead target cells
(upper right), live effector cells (lower left) and dead effector
cells (lower right).
2.6. Statistics
Data are expressed as mean counts ± standard deviation.
Sample size for CD94 expression was calculated and was
equivalent to n = 13 (a = 0.05; power = 0.8; difference = 3.5;
S.D. = 2.6). The Mann Whitney U-test was used for compari-
son between patient groups. The paired t test was used for
the comparisons of data from cytotoxic assays or for compar-
ing intracellular and membrane expression of CD94/NKG2A
in pleural cells from cancer patients. p < 0.05 was accepted
as statistically significant.
3. Results
3.1. CD8+ CTL and NK cells in cancer and in CHF patients
Altered numbers of NK and CD8+ cells or functional defects of
these cell types may contribute to reduce the efficiency of theTable 1 – Phenotype of the cells from PF and PB.
CD3+ CD3+CD4+ CD
Cancer PF 77 ± 19 60 ± 17 17
Cancer PB 57 ± 25 35.4 ± 17 19
CHF PF 75.6 ± 18 57.5 ± 20 18
CHF PB 69.5 ± 19 44.8 ± 21 26
Data are expressed as % of positive cells.
* p < 0.05 PF versus PB.immune responses against cancer cells.3,4 The first step of
this study was to assess whether the altered numbers of
CD8+ and NK cells were specifically present in malignant PF
comparing malignant PF and PB from cancer patients with
PF and PB from CHF patients.
Whilst no significant differences were observed in the per-
centage of CD8+ CTL between cancer and CHF patients in the
two studied compartments (PF and PB), the percentage of NK
cells was reduced in PF from both cancer and CHF patients in
comparison to autologous PB (Table 1).3.2. Membrane CD94/NKG2A expression in CD8+ CTL
and NK cells of cancer and CHF patients
CD8+ CTL and NK cells express inhibitory receptors to re-
strain their ‘lethal’ behaviour.6 Therefore, we assessed
whether the expression of the inhibitory receptor CD94/
NKG2A was altered in the total lymphocyte population iso-
lated frommalignant PF comparing malignant PF and PB from
cancer patients with PF and PB from CHF patients.
The membrane expression of CD94/NKG2A was signifi-
cantly (p < 0.05) reduced in malignant PF in comparison to
autologous PB and in comparison to CHF PF (Fig. 1). We fur-
ther assessed whether this reduced expression of CD94/
NKG2Awas related to CD8+ CTL or to NK cells. The expression
of CD94/NKG2A by CD8+ CTL was significantly (p < 0.05) re-
duced in malignant PF in comparison to autologous PB and
in comparison to CHF PF (Fig. 2). The expression of CD94/
NKG2A by NK cells was significantly (p < 0.05) reduced in
malignant PF in comparison to autologous PB but not in com-
parison to CHF PF (Fig. 3).3.3. Perforin expression in CD8 CTL and NK cells of cancer
and CHF patients
CD8+ CTL and NK cells kill tumour target cells relying on di-
rected exocytosis of secretory lysosomes, including perforin.4
Therefore, we assessed whether the expression of perforin
was altered in cells obtained frommalignant PF by comparing
their activity with those of cells from autologous PB and from
PF and PB of CHF patients.
The expression of perforin was significantly (p < 0.05) re-
duced in malignant PF in comparison to autologous PB and
in comparison to CHF PF (Fig. 4). Furthermore, the expression
of perforin was significantly (p < 0.05) reduced in both CD8+
CTL (Fig. 5) and in NK (Fig. 6) cells in malignant PF in compar-
ison to autologous PB.3+CD8+ CD3–CD19+ CD3–CD56+CD16+
± 6.6 6.9 ± 5.6 3.4 ± 3*
.3 ± 14 6.8 ± 5 15 ± 10
.7 ± 10 3.5 ± 2.8 5.8 ± 5*
.2 ± 16 4.8 ± 2.3 14 ± 11
Fig. 1 – CD94/NKG2A expression in cancer and CHF patients. Pleural and peripheral blood mononuclear cells were isolated
from malignant (n = 19) and from CHF (n = 11) pleural fluids and CD94/NKG2A expression was assessed by flow-cytometry in
the lymphocytes gated by forward and side scatter (see Section 2 for details) using a FITC conjugated antibody. Data are
expressed as percentage of positive cells (mean ± S.D.) (A). *p < 0.05 (Mann Whitney U-test). (B) Representative dot plots that
show the percentage of total lymphocytes expressing CD94/NKG2A.
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Since both CD8+ CTL and NK cells present in malignant PF
showed reduced expression of perforin when compared to
autologous PB and in comparison to CHF PF, we tested their
in vitro cytotoxic activity against epithelial cancer cells. In
cancer patients, the cytotoxic activity of cells isolated from
PF was reduced when compared to the cytotoxic activity ofFig. 2 – CD94/NKG2A expression in CD8+ cells from cancer and C
were isolated from malignant (n = 19) and from CHF (n = 11) pleu
assessed by flow-cytometry in the lymphocytes gated by forwa
conjugated antibody for CD94/NKG2A and a PE conjugated antib
cells (mean ± S.D.) (A). *p < 0.05 (Mann Whitney U-test). (B) Repre
expressing CD94/NKG2Acells isolated from autologous PB peripheral blood and from
CHF PF (Fig. 7).
3.5. Intracellular CD94/NKG2A expression in CD8 and NK
cells of cancer
Since pleural cells from cancer patients had a reduced mem-
brane expression of the inhibitory receptor CD94/NKG2A butHF patients. Pleural and peripheral blood mononuclear cells
ral fluids and CD94/NKG2A expression in CD8+ cells was
rd and side scatter (see Section 2 for details) using a FITC
ody for CD8. Data are expressed as percentage of positive
sentative dot plots that show the percentage of CD8+ cells
Fig. 3 – CD94/NKG2A expression in CD56+/CD16+ cells from cancer and CHF patients. Pleural and peripheral blood
mononuclear cells were isolated from malignant (n = 19) and from CHF (n = 11) pleural fluids and CD94/NKG2A expression in
double positive CD16+/CD56+ (NK) cells was assessed by flow-cytometry (see Section 2 for details) using a FITC conjugated
antibody for CD94/NKG2A and a PE-anti CD16 and PE-Cy5 anti-CD56 conjugated antibodies. Data are expressed as percentage
of positive cells (mean ± S.D.) (A). *p < 0.05 (Mann Whitney U-test). (B) Representative dot plots that show the percentage of
CD56/CD16+ cells expressing CD94/NKG2A.
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activity against cancer cells and since upon the activation of
CD94/NKG2A this receptor is internalised (and therefore no
longer on the surface),11 we studied the intracellular expres-
sion of CD94/NKG2A. In total T lymphocyte population
(Fig. 8A), in CD8+ CTL (Fig. 8B) and in NK cells (Fig. 8C) from
malignant PF, the intracellular expression of CD94/NKG2A
was significantly (p < 0.05) higher than the membrane expres-
sion of CD94/NKG2A.Fig. 4 – Perforin expression in cancer and CHF patients. Pleural
malignant (n = 19) and from CHF (n = 11) pleural fluids and perfo
lymphocytes gated by forward and side scatter (see Section 2 fo
expressed as percentage of positive cells (mean ± S.D(A). *p < 0.0
Representative dot plots that show the percentage of total lymp4. Discussion
CD8+ CTL and NK cells display effector functions, including
the recognition and lysis of infected, stressed, or transformed
cells and the production of immunoregulatory cytokines and
chemokines.12 Tumour microenvironment may be unfavour-
able for CD8+ CTL and NK cell activity and may contribute
to tumour immune escape. Malignant effusions are a rela-
tively easily accessible source of tumour-associated effectorand peripheral blood mononuclear cells were isolated from
rin expression was assessed by flow-cytometry in the
r details) using a FITC conjugated antibody. Data are
5 (Mann Whitney U-test); **p < 0.05 (paired t test). (B)
hocytes expressing perforin.
Fig. 5 – Perforin expression in CD8+ cells from cancer and CHF patients. Pleural and peripheral blood mononuclear cells were
isolated from malignant (n = 19) and from CHF (n = 11) pleural fluids and perforin expression in CD8+ cells was assessed by
flow-cytometry in the lymphocytes gated by forward and side scatter (see Section 2 for details) using a FITC conjugated
antibody for perforin and a PE conjugated antibody or CD8. Data are expressed as percentage of positive cells (mean ± S.D.)
(A). *p < 0.05 (Mann Whitney U-test). (B) Representative dot plots that show the percentage of CD8+ cells expressing perforin.
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tions between tumour cells and the host immune system.
Although, it is well known that specific cancers, such as lung
cancer or cancer of the breast, ovary and stomach preferen-
tially metastasise the pleural compartment,1 the mechanisms
that promote a predilection for the pleural compartment are
not fully elucidated. We previously demonstrated that pleural
inflammation generates an ideal microenvironment to attract
cancer cells, to promote their growth and their protectionFig. 6 – Perforin expression in CD56+/CD16+ cells from cancer a
cells were isolated from malignant (n = 19) and from CHF (n = 11
CD16+/CD56+ (NK) cells was assessed by flow-cytometry in the l
for details) using a FITC conjugated antibody for perforin and a
Data are expressed as percentage of positive cells (mean ± S.D.)
plots that show the percentage of CD56/CD16+ cells expressingwhen exposed to toxic agents.2 The present study was aimed
at extending these findings by investigating whether the
recruitment and the accumulation of specific subsets of lym-
phocytes in the malignant effusions may contribute to these
cancer protective events within the pleural compartment.
We have found that pleural CD8+ CTL from cancer pa-
tients show a reduced expression of CD94/NKG2A when
compared to autologous PB and to CHF PF and a reduced
expression of perforin when compared to autologous PB.nd CHF patients. Pleural and peripheral blood mononuclear
) pleural fluids and perforin expression in double positive
ymphocytes gated by forward and side scatter (see Section 2
PE-anti CD16 and PE-Cy5 anti-CD56 conjugated antibodies.
(A). *p < 0.05 (Mann Whitney U-test). (B) Representative dot
perforin.
Fig. 7 – Cytotoxic activity against cancer cells. Pleural and peripheral blood mononuclear cells and pleural mononuclear cells
were isolated from cancer (n = 8) and from CHF (n = 8) patients, respectively and a flow cytotoxic assay against H292 cancer
cells was performed using the DiO membrane dye and propidium iodide (PI) (see Section 2 for details). Data are expressed as
percentage of cytotoxic activity versus baseline (=H292 cultured in medium alone) (A). *p < 0.05 (paired t test). (B)
Representative dot plots from a cancer patient that show the percentage of DiO positive (cancer cells) or negative cells
expressing PI.
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and CHF patients, and these cells in malignant PF have a re-
duced expression of membrane CD94/NKG2A and of perforin
in comparison to autologous PB. Moreover, pleural lympho-
cytes from cancer patients with higher intracellular CD94/
NKG2A expression exhibit a reduced cytotoxic activity
against cancer cells when compared to autologous PB T lym-
phocytes and to CHF PF.
CD94/NKG2A is expressed on NK cells and on CD8+ CTL.
The CD94/NKG2 heterodimer is a C-type lectin receptor,
formed by the covalent association of CD94, a protein with a
short non-signalling intracytoplasmic tail and one of the
NKG2 molecules, namely NKG2A, -B, -C or -E. The intracellu-
lar domain of NKG2A contains immunoreceptor tyrosine-
based inhibition motifs (ITIMs), responsible for transducing
inhibitory signals, useful to limit exaggerated activation of
NK cells and of CD8+ CTL. In humans, CD94/NKG2A is acti-
vated upon the interaction with complexes of non-classical
HLA-E molecules.11 Consequently, the modulation of the li-
gands of CD94/NKG2A on the surface of cancer cells may af-
fect the functional activation of effector cells.
CD8+ CTL play an important role in cell-mediated immune
responses. They are capable of inducing the death of cancer
cells by the release of perforin and granulysin. Perforin forms
pores in the plasma membrane of target cell allowing gran-
zymes types of serine proteases, to enter the target cell,
which then activates a series of enzymes, the caspase cas-
cade that eventually lead to apoptosis.13
Human NK cells are generally recognised as sentinels of
the innate immune system due to their inherent capacity to
deal with diseased (stressed) cells, including malignant
cells.14 More than 90% of circulating NK cells express moder-
ate levels of CD56 (CD56dim NK cells) and high levels of CD16
and are heterogeneous in the expression of CD94 and NKG2A
molecules.
The minor subset of NK cells expresses high levels of CD56
(CD56bright), CD94 and NKG2A, tends to lack the expression
of CD1615 and have been found to be enriched in human sec-
ondary lymphoid organs and in chronic inflammatory sites.16NK infiltrating human non-small lung cancer are character-
ised by the high expression of CD56 and have a reduced abil-
ity to kill cancer cells.17
In our study, a significant reduction of membrane CD94/
NKG2A expression and of perforin was observed in CD8+
CTL and in NK cells isolated frommalignant PF in comparison
to those isolated from autologous PB. Furthermore, a signifi-
cant reduction of membrane CD94/NKG2A expression and
of perforin was observed in CD8+ CTL isolated from malig-
nant PF in comparison to those isolated from CHF PF, suggest-
ing that these changes in the phenotype of the recruited cells
may be generated by the presence of an inflammatory milieu
into the pleural compartment. This finding is specific for exu-
dative malignant effusions since in exudative tuberculous PF
there is an accumulation of subsets of NK cells that are char-
acterised by low expression of perforin but higher expression
of CD94/NKG2A and higher levels of IFNg in comparison to
the PB counterparts.15
The distribution of T lymphocyte subsets in various organ
compartments is very different than the distribution of sub-
sets in the peripheral blood. This compartmentalisation is
essential for optimal host defence. Pleural microenvironment
(cells and mediators) tightly participates in the regulation of
immune responses within the pleural space.18,19 Selective
recruitment20–22 or selective cell apoptosis23 may affect the
accumulation of specific cells in the pleural compartment
during inflammation. Peripheral blood CD16 positive cells
with low expression of CD56 are more susceptible to undergo
apoptosis in tuberculosis pleural effusions leading to an
enrichment in activated CD16 negative cells with high expres-
sion of CD56.15 Moreover, PGE2 released in malignant pleural
effusions protect T lymphocyte from apoptosis and this pro-
tective effect is mainly exerted on the CD45RO+ T cells rather
than on CD45RA+ T cells.23
Consistently, the majority of CD8+ T lymphocytes in the
pleural compartment expresses CD45RO,24 a surface molecule
that has been correlated with the memory phenotype and
granzymes but not perforin or expresses perforin at a low le-
vel.24 In addition CD94 down-regulation may contribute to
Fig. 8 – Intracellular expression of CD94/NKG2A in pleural cells from cancer patients. Pleural mononuclear cells were isolated
from malignant pleural effusions (n = 10) and the membrane and intracellular CD94/NKG2A expression was evaluated (see
Section 2 for details). Data are expressed as percentage of CD94/NKG2A positive cells. *p < 0.05 (paired t test).
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expression correlates with the survival of CD8+ CTL and NK
cells.25 A preferential cell apoptosis in the terminally differen-
tiated CD8+ CTL and NK effector cells could result in a
reduced efficiency of immune responses. In this regard,
down-regulation of CD94/NKG2A on CD8+ CTL and NK cells
has been observed in advanced HIV infection.26 In addition,
activated CD4+ T cells that fail to engage inhibitory NKG2A
receptors on the membrane of NK cells are also susceptible
to NK cell lysis. Consequently, the reducedmembrane expres-
sion of NKG2A receptors in malignant PF might negatively
affect the development of adaptive responses in this com-
partment. In this regard, it has been previously demonstrated
that patients with malignant effusions show a deficient
enrichment of T cells expressing the phenotype of type-1-
polarised effector T cells at the tumour site.8
Although, CD8+ CTL and NK cell recovered from cancer PF
have a reduced expression of the inhibitory receptor CD94/
NKG2A, they exhibit a reduced cytotoxic activity against can-
cer cells when compared to CD8+ CTL and NK cells recovered
from autologous PB. NKG2A receptor deficiency may contrib-
ute to this reduced cytotoxic activity by two mechanisms: (1)
high concentrations of IFN-c increase the levels of HLA-E
which activate the receptor thus promoting its internalisation
(being the receptor no longer on the surface)11; (2) the lack of
the NKG2A receptor enhances regulatory functions with an
advantage for the tumour cell. In this regard, it has been dem-
onstrated that genetic disruption of the NKG2A–Qa-1 interac-
tion in mice releases the brakes on CD8-dependent
suppressive activity, allowing the development of robustCD8- Treg activity.27 These CD8+ cells with Treg activity also
express low levels of granzyme B and perforin, suggesting
that these cells do not possess killing potential.28 Addition-
ally, perforin deficiency increases the susceptibility to
cancer.13
Indeed, these concepts are consistent with our present
findings, in that CD8+ CTL and NK cells from malignant PF
have elevated intracellular expression of CD94/NKG2A (i.e.
activated form of receptor), undetectable perforin expression
and a reduced ability to lyse tumour target cells. Further-
more, it has been previously demonstrated that reduced
number of NK and increased numbers of regulatory T cells
are observed in malignant lung tissue in non-small cell lung
cancer.29
In conclusion, this study identifies new mechanisms pro-
moting the development and persistence of a compartmenta-
lised pleural inflammation as well as a reduced host defence
mechanism against cancer within the pleural space.Conflict of interest statement
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